When COVID-19 began spreading globally in early 2020, most official guidance focused on staying home, waiting, and going to the hospital when severely ill. A group of critical care physicians decided that was not good enough. They began systematically reviewing every piece of evidence available and developing early outpatient treatment protocols based on the best available science.
The result was the Front Line COVID-19 Critical Care Alliance (FLCCC), founded by Drs. Paul Marik and Pierre Kory — two of the most published critical care physicians in the country. What they produced, and what it cost them professionally, is one of the defining medical freedom stories of our era.
The I-MASK+ Protocol
The FLCCC's outpatient protocol for early COVID treatment — called I-MASK+ — combined several repurposed medications based on mechanistic rationale and early clinical evidence. Ivermectin was the centerpiece, given its documented ability to inhibit viral entry into cells and modulate immune response. Azithromycin was included for its immunomodulatory and potential antiviral properties — not just as an antibiotic.
The azithromycin Z-pack had already been part of early hospital protocols in France and elsewhere. Dr. Didier Raoult's team in Marseille had treated thousands of patients with azithromycin plus HCQ with reported success. The FLCCC synthesized this global experience into a coherent, evidence-based framework.
Azithromycin as Immune Modulator
Most people think of azithromycin as simply an antibiotic. But research has documented significant immunomodulatory effects — it reduces production of pro-inflammatory cytokines, including the very cytokines that drive the "cytokine storm" responsible for severe COVID-19. Studies have also shown direct antiviral activity against several respiratory viruses.
In the context of a respiratory infection, azithromycin serves a dual purpose: preventing secondary bacterial pneumonia (a major cause of COVID mortality) and dampening the inflammatory cascade that causes acute respiratory distress syndrome. This mechanistic rationale is why it appeared in multiple early treatment protocols independently.
What the Suppression Tells Us
Dr. Pierre Kory's Senate testimony in December 2020 — where he presented extensive evidence for ivermectin efficacy — was viewed millions of times before being removed from major platforms. Dr. Marik was sued by his own hospital for continuing to treat patients with protocols he believed were saving lives.
These were not fringe doctors. These were accomplished, published, credentialed physicians whose clinical judgment was overridden by institutional and regulatory pressure. Their story is a cautionary tale about what happens when bureaucracy supersedes medical expertise — and a testament to what genuine medical courage looks like.
Your Right to Know
The FLCCC protocols remain available at their website. Thousands of physicians worldwide use them. If you want access to medications that support these protocols — ivermectin, azithromycin, HCQ — you have the right to seek them and to have an honest conversation with your physician. Medical sovereignty begins with information.
Key Takeaway: The FLCCC protocol combined ivermectin's antiviral properties with azithromycin's immunomodulatory effects in a scientifically coherent early-treatment framework — and the suppression of this protocol should concern every American who believes in medical freedom.